Q1 Earnings Forecast for ELVN Issued By HC Wainwright

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – HC Wainwright issued their Q1 2026 EPS estimates for Enliven Therapeutics in a report released on Thursday, May 15th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.67) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.71) EPS and Q4 2026 earnings at ($0.73) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Separately, Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $37.25.

Enliven Therapeutics Stock Down 5.4%

Shares of Enliven Therapeutics stock opened at $16.86 on Friday. The company has a market capitalization of $827.25 million, a price-to-earnings ratio of -8.87 and a beta of 1.07. The stock’s 50-day simple moving average is $18.84 and its 200-day simple moving average is $21.70. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.03.

Insider Buying and Selling at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 5,030 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $20.07, for a total transaction of $100,952.10. Following the sale, the insider now directly owns 992,658 shares of the company’s stock, valued at $19,922,646.06. This represents a 0.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the transaction, the chief operating officer now owns 323,310 shares of the company’s stock, valued at $6,931,766.40. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,111 shares of company stock worth $1,493,145. Insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently bought and sold shares of the business. Franklin Resources Inc. purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth $559,000. SG Americas Securities LLC lifted its holdings in shares of Enliven Therapeutics by 66.1% in the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock valued at $374,000 after acquiring an additional 6,616 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after acquiring an additional 1,275 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Enliven Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock worth $5,892,000 after acquiring an additional 6,611 shares during the last quarter. Finally, Swiss National Bank raised its position in Enliven Therapeutics by 13.9% during the fourth quarter. Swiss National Bank now owns 41,873 shares of the company’s stock valued at $942,000 after purchasing an additional 5,100 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.